• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 5. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indolines

Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid (CAS No. 356068-93-4): A Comprehensive Overview

Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid (CAS No. 356068-93-4) is a derivative of the well-known tyrosine kinase inhibitor, sunitinib. This compound has garnered significant attention in the field of medicinal chemistry and oncology due to its potential therapeutic applications and unique structural modifications. In this comprehensive overview, we will delve into the chemical properties, biological activities, and recent research advancements of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid.

Chemical Structure and Synthesis

The chemical structure of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid is characterized by the removal of the N-(2-diethylaminoethyl)amide group from the parent compound, sunitinib. This modification significantly alters the pharmacological profile of the molecule, potentially enhancing its selectivity and reducing off-target effects. The synthesis of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid involves a series of well-defined chemical reactions, including deprotection, amidation, and purification steps. Recent studies have explored various synthetic routes to optimize yield and purity, making the compound more accessible for further research and development.

Biological Activities

Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid exhibits potent inhibitory activity against multiple tyrosine kinases, including VEGFR, PDGFR, and KIT. These kinases play crucial roles in angiogenesis, cell proliferation, and survival, making them attractive targets for cancer therapy. Preclinical studies have demonstrated that Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid effectively inhibits tumor growth in various cancer models, including renal cell carcinoma (RCC), gastrointestinal stromal tumors (GIST), and pancreatic neuroendocrine tumors (PNET). The compound's ability to target multiple kinases simultaneously suggests a broad-spectrum antitumor activity.

Pharmacokinetics and Toxicology

The pharmacokinetic properties of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid have been extensively studied to understand its absorption, distribution, metabolism, and excretion (ADME). In vitro and in vivo experiments have shown that the compound has favorable pharmacokinetic profiles, with good oral bioavailability and a reasonable half-life. However, like many small molecule inhibitors, Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid can exhibit dose-dependent toxicity. Preclinical toxicology studies have identified potential side effects such as gastrointestinal disturbances and cardiovascular toxicity. These findings highlight the importance of optimizing dosing regimens to maximize therapeutic benefits while minimizing adverse effects.

Clinical Trials and Therapeutic Potential

The therapeutic potential of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid is currently being evaluated in several clinical trials. Early-phase trials have demonstrated promising results in patients with advanced or metastatic cancers. For instance, a phase I/II trial evaluating the safety and efficacy of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid in patients with advanced RCC showed significant tumor shrinkage and prolonged progression-free survival. These findings have paved the way for further clinical investigations to explore its efficacy in other cancer types.

Recent Research Advancements

Recent advancements in the field have shed light on the mechanisms underlying the antitumor activity of Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid. Studies using advanced techniques such as next-generation sequencing (NGS) and proteomics have identified novel biomarkers that can predict response to treatment. For example, mutations in specific kinases or signaling pathways have been associated with increased sensitivity to Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid. These biomarkers can help personalize treatment strategies and improve patient outcomes.

Conclusion

In conclusion, Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid (CAS No. 356068-93-4) represents a promising therapeutic agent with significant potential in oncology. Its unique structural modifications confer enhanced selectivity and reduced toxicity compared to its parent compound, sunitinib. Ongoing research continues to uncover new insights into its biological activities and clinical applications. As more data from clinical trials become available, it is anticipated that Des-N-(2-Diethylaminoethyl)amide Sunitinib Acid will play a crucial role in advancing cancer therapy.

• 452105-33-8(5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)